Health Care • Biotechnology: Pharmaceutical Preparations
$129.53 ▼ -10.16
(-7.27%)
MKT CAP: $5.84B • VOL: 636.8K
52W L $32 52W H $147
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$109
MEDIAN
$145
MEAN
$148
HIGH
$176
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MANE TAPE
MANE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $156.73 | $148.96 | 2025-02-14 | $117.87 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $163.21 | $152.85 | 2025-02-06 | $121.76 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $147.66 | $142.48 | 2025-01-29 | $124.35 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $132.12 | — | 2025-01-17 | $126.94 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $113.99 | $123.05 | 2025-01-09 | $115.28 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $154.14 | $134.71 | 2024-12-18 | $112.69 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $125.64 | $130.83 | 2024-12-04 | $120.46 | -4.3% | 48% | C |